1. Aman, M. G., Arnold, L. E., McDougle, C. J., Vitiello, B., Scahill, L., Davies, M., et al. (2005). Acute and long-term safety and tolerability of risperidone in children with autism. Journal of Child and Adolescent Psychopharmacology, 15(6), 869–884.
2. Aman, M. G., & Singh, N. N. (1994). Aberrant behavior checklist—community. (supplementary manual). East Aurora, NY: Slosson Educational Publication.
3. Aman, M. G., Singh, N. N., Stewart, A. W., & Field, C. J. (1985a). The Aberrant Behavior Checklist: A behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiency, 89(5), 485–491.
4. Aman, M. G., Singh, N. N., Stewart, A. W., & Field, C. J. (1985b). Psychometric characteristics of the Aberrant Behavior Checklist. American Journal of Mental Deficiency, 89(5), 492–502.
5. Aman, M. G., Vinks, A. A., Remmerie, B., Mannaert, E., Ramadan, Y., Masty, J., et al. (2007). Plasma pharmacokinetics characteristics of risperidone and their relationship to saliva concentrations in children with psychiatric or neurodevelopmental disorder. Clinical Therapeutics, 29, 1476–1486.